Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Cash: 2010-2025

Historic Change in Cash for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $96.8 million.

  • Arrowhead Pharmaceuticals' Change in Cash rose 234.30% to $96.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.3 million, marking a year-over-year increase of 1101.89%. This contributed to the annual value of $124.3 million for FY2025, which is 1101.89% up from last year.
  • Arrowhead Pharmaceuticals' Change in Cash amounted to $96.8 million in Q3 2025, which was up 272.79% from -$56.0 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Cash ranged from a high of $232.5 million in Q1 2021 and a low of -$141.5 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Cash was -$29.5 million (2023), whereas its average is $1.9 million.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 2,434.35% in 2021, then soared by 435.71% in 2024.
  • Arrowhead Pharmaceuticals' Change in Cash (Quarterly) stood at -$92.8 million in 2021, then soared by 201.68% to $94.4 million in 2022, then plummeted by 155.88% to -$52.7 million in 2023, then increased by 7.60% to -$48.7 million in 2024, then spiked by 234.30% to $96.8 million in 2025.
  • Its Change in Cash was $96.8 million in Q3 2025, compared to -$56.0 million in Q2 2025 and $132.2 million in Q1 2025.